<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We previously reported that orthovanadate composed of vanadate (V(5+)) activates phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling through inhibition of protein tyrosine phosphatases, thereby eliciting neuroprotection in <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>/reperfusion injury </plain></SENT>
<SENT sid="1" pm="."><plain>However, therapeutic doses of orthovanadate are associated with <z:hpo ids='HP_0002014'>diarrhea</z:hpo> due to inhibition of ATPase </plain></SENT>
<SENT sid="2" pm="."><plain>By contrast, vanadyl (V(4+)) organic compounds show low cytotoxicity </plain></SENT>
<SENT sid="3" pm="."><plain>Since both vanadate and vanadyl inhibit protein tyrosine phosphatases, we tested whether bis(1-oxy-2-pyridinethiolato)oxovanadium(IV) [VO(OPT)] in a vanadyl form elicits a neuroprotection in <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In a mouse transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) model, pre- and post-treatments with VO(OPT) significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in a dose-dependent manner </plain></SENT>
<SENT sid="5" pm="."><plain>Like orthovanadate, activation of the PI3K/Akt pathway mediated neuroprotective action </plain></SENT>
<SENT sid="6" pm="."><plain>VO(OPT) treatment inhibited reduced Akt phosphorylation at Ser-473 following <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> and restored decreased phosphorylation of forkhead box class O (FOXO) family members such as FKHR, FKHRL1, and AFX </plain></SENT>
<SENT sid="7" pm="."><plain>Consistent with inhibition of FOXO dephosphorylation, VO(OPT) treatment blocked elevated expression of Fas-ligand, <z:chebi fb="3" ids="33173">Bim</z:chebi> and active caspase-3 24 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion </plain></SENT>
<SENT sid="8" pm="."><plain>Taken together, a vanadyl compound, VO(OPT) elicits neuroprotective effects on <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>/reperfusion injury without apparent side effects </plain></SENT>
</text></document>